WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY

• Total Revenue Reached RMB11.14 Billion in the Second Quarter, Up 20.4% Year-over-Year; among which Revenue from Continuing Operations Reached RMB11.05 Billion, Up 24.9% Year-over-Year
• Total Revenue Reached RMB20.80 Billion for the First Half, Up 20.6% Year-over-Year; among which Revenue from Continuing Operations Reached RMB20.41 Billion, Up 24.2% Year-over-Year
• Net Profit Attributable to the Owners of the Company Reached RMB8.56 Billion ^[2] for the First Half, Up 101.9% Year-over-Year; Diluted Earnings per Share (EPS) of RMB2.99 ^[3], Up 106.2% Year-over-Year
• Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB6.31 Billion for the First Half, Up 44.4% Year-over-Year; Adjusted Non-IFRS Diluted EPS of RMB2.20, Up 46.7% Year-over-Year
• Backlog for Continuing Operations Reached RMB56.69 billion as of June 30, 2025, Up 37.2% Year-over-Year
• Operating Cash Flow Achieved RMB7.07 Billion for the First Half, Up 49.1% Year-over-Year

SHANGHAI, July 28, 2025 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first half ending June 30, 2025 ("Reporting Period"):

• For the first half of 2025, total revenue reached RMB20.80 billion, up 20.6% year-over-year. Revenue from Continuing Operations reached RMB20.41 billion, up 24.2% year-over-year.
• Adjusted non-IFRS gross profit reached RMB9.26 billion, with the adjusted non-IFRS gross profit margin up 4.7pts year-over-year to 44.5%.
• Net profit attributable to the owners of the Company was RMB8.56 billion, up 101.9% year-over-year; diluted EPS was RMB2.99, up 106.2% year-over-year.
• Adjusted non-IFRS net profit attributable to the owners of the Company was RMB6.31 billion, up 44.4% year-over-year; adjusted non-IFRS net profit margin up 5.0pts year-over-year to 30.4%; adjusted non-IFRS diluted EPS was RMB2.20, up 46.7% year-over-year.
• With continuous capacity expansion to better meet customer demand, backlog for Continuing Operations reached RMB56.69 billion as of June 30, 2025, up 37.2% year-over-year.
• Operating cash flow climbed 49.1% year-over-year to RMB7.07 billion, driven by business growth, increase in operating efficiency, and continued improvement of financial management capabilities.
• The Company's sustained and steady business growth is the result of our unique, fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform. Driven by "follow the molecule" and "win the molecule" strategies, WuXi Chemistry's small molecule CRDMO pipeline continues to efficiently convert and capture high-quality molecules, delivering sustained business growth. In the first half of 2025, a total of 412 new molecules have been added to the small molecule Development and Manufacturing (D&M) pipeline. As of June 30, 2025, our small molecule D&M pipeline reached 3,409 molecules, representing an increase of 8 projects in phase III and commercial stages during the first half of 2025.
• The Company has been accelerating global expansion and capacity construction. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with no single observation. By the end of 2025, total reactor volume of small molecule APIs is expected to reach over 4,000kL, and the total reactor volume of Solid Phase Peptide Synthesizers is expected to increase to more than 100,000L.
• As an enabler of innovation and a trusted partner and contributor to the global pharmaceutical and life sciences industry, the Company actively advanced sustainability and has been extensively recognized by global rating agencies. The Company has achieved the highest "AAA" rating from MSCI for the first time, becoming the first A-share listed company in the life sciences industry to achieve this milestone. In addition, the Company's near-term emissions reduction targets have been validated by Science Based Targets initiatives (SBTi). Our accomplishments have also been acknowledged by major global rating agencies, including EcoVadis, CDP, United Nations Global Compact (UNGC), Sustainalytics and FTSE Russell.
• The Company remains committed to rewarding shareholders and actively supporting the Company's value. In the first half of 2025, the Company distributed a total of RMB3.84 billion in cash dividends, including RMB2.83 billion for the 2024 annual cash dividend and RMB1.01 billion for the 2025 special cash dividend. Meanwhile, the Company also completed the repurchase and cancellation of RMB1.0 billion worth of A-shares in the first half. An additional, previously announced RMB1.0 billion worth of A-share repurchase and cancellation plan is currently being implemented, with approximately RMB0.5 billion worth of A-shares repurchased as of now. Moreover, the Company's Board of Directors approved WuXi AppTec's first interim dividend plan, distributing RMB3.50 cash dividend for every 10 shares (approximately RMB1.0 billion in total) to shareholders.

[1] As disclosed in 2025 Interim Report, Continuing Operations include WuXi Chemistry, WuXi Testing, WuXi Biology and Others, the scope of which may change following adjustments to the Company's business strategy.

[2] Net profit attributable to the owners of the Company is prepared in accordance with China Accounting Standards for Business Enterprises (CAS).

[3] In 2024 H1 and 2025 H1, WuXi AppTec had a fully-diluted weighted average share count of 2,913,355,532 and 2,897,449,552 ordinary shares, respectively.

2025 Full-Year Outlook

With confidence in customers' ongoing demand for enabling services, our CRDMO business model and management execution, the Company has raised full-year guidance despite external uncertainties.

The Company expects Continuing Operations revenue to resume double-digit growth in 2025, with its year-over-year growth rate raised to 13-17%, up from the prior 10-15%. As a result, the Company expects full-year total revenue of RMB42.5 -43.5 billion, up from the prior RMB41.5 -43.0 billion.

As it focuses on the core CRDMO business and continuously improved production and operating efficiency, the Company is confident and expects to further improve the adjusted non-IFRS net profit margin in 2025.

Capex is expected to reach RMB7.0 -8.0 billion in 2025. Together with business growth and efficiency improvement, free cash flow is expected to increase from RMB4.0 -5.0 billion to RMB5.0 -6.0 billion.

Management Comment

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "WuXi AppTec once again delivered robust double-digit growth in both revenue and profit in the second quarter, demonstrating the strength of our unique CRDMO business model and the dedication of our global teams. In the first half of 2025, we achieved revenue of RMB20.8 billion, with Continuing Operations revenue growing 24.2% year-over-year, and adjusted non-IFRS net profit growing 44.4% year-over-year, while our backlog for Continuing Operations reached a new record high of RMB56.7 billion."

"Building on this strong momentum and consistent execution, we have raised our 2025 full-year revenue target to RMB42.5 -43.5 billion, with Continuing Operations now expected to achieve 13-17% year-over-year double-digit growth, and correspondingly, the free cash flow target up to RMB5.0 -6.0 billion. We remain focused on enhancing our core capabilities, expanding capacity, and improving operating efficiency to create greater value for our customers and shareholders."

"Guided by our vision that 'Every drug can be made and every disease can be treated,' we are committed to enabling our partners to deliver innovative therapies to patients worldwide. Together, we will continue to advance healthcare innovation and improve lives."

Business Performance by Segments

• WuXi Chemistry: CRDMO Business Model Drives Continuous Growth; H1 2025 Revenue Up 33.5% YoY, with TIDES Revenue Up 141.6% YoY
  • H1 revenue of WuXi Chemistry reached RMB16.30 billion, up 33.5% year-over-year. With continued optimization of production process and improvement in capacity efficiency driven by the growth of late-stage clinical and commercial projects, H1 adjusted non-IFRS gross profit margin steadily improved 5.2pts year-over-year to 49.0%.
  • Small molecule drug discovery service ("R") continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 440,000 new compounds to customers. In the meantime, 158 molecules were converted from R to D phase in the first half of 2025.Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our customers globally, supporting the sustainable growth of our CRDMO business.
  • Small molecule D&M service remains strong.
    • i. The small molecule CDMO pipeline continued to expand. H1 revenue of small molecule D&M services rose 17.5% year-over-year to RMB8.68 billion. In the first half of 2025, 412 new molecules were added to the small molecule D&M pipeline. As of June 30, 2025, our small molecule D&M pipeline reached 3,409 molecules, including 76 commercial projects, 84 in phase III, 368 in phase II and 2,881 in phase I and pre-clinical stages. That represents an increase of 8 projects in the commercial and phase III stages during the first half of 2025.
    • ii. We continued to build small molecule capacity. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with no single observation. The total reactor volume of small molecule APIs is expected to reach over 4,000kL by the end of 2025.
  • TIDES business (oligo and peptides) sustains rapid growth.
    • i. With the ramp-up of new capacities released sequentially each quarter last year, H1 TIDES revenue grew 141.6% year-over-year to RMB5.03 billion. As of June 30, 2025, TIDES backlog was up 48.8% year-over-year.
    • ii. TIDES D&M customers grew 12% year-over-year, while the number of TIDES molecules grew 16% year-over-year.
    • iii. We continued to build peptide capacity in Taixing. Total reactor volume of Solid Phase Peptide Synthesizers is expected to increase to over 100,000L by the end of 2025.
• WuXi Testing^[4]: Drug Safety Evaluation Service & Site Management Organization (SMO) Maintain Leading Positions
  • WuXi Testing revenue reached RMB2.69 billion in H1, and H1 adjusted non-IFRS gross profit margin was 25.1%.
  • Q2 revenue of lab testing services reached RMB1.00 billion, growing 5.5% year-over-year and 13.2% quarter-over-quarter. Of which, drug safety evaluation services revenue grew 3.4% year-over-year and 10.2% quarter-over-quarter.
  • H1 revenue of lab testing services grew 0.4% year-over-year to RMB1.89 billion. Due to market impact, its H1 adjusted non-IFRS GPM declined as pricing gradually reflected in revenue along with backlog conversion. Of which, drug safety evaluation services revenue was down 2.2% year-over-year, while maintaining an industry-leading position in the Asia-Pacific region.
  • The Company is committed to actively enabling customers' global licensing. New modality business continued to develop, while the Company maintained its leading position in areas including nucleic acids, conjugates, mRNA, multispecific antibodies and peptides.
  • The Suzhou facility has successfully passed 4 consecutive FDA on-site inspections.
  • H1 revenue for clinical CRO & SMO declined 4.7% year-over-year to RMB0.80 billion due to market pricing impact. Of which, SMO revenue grew 1.5% year-over-year and maintained the industry leading position in China.
  • During the first half of 2025, our clinical CRO business supported customers to obtain 12 IND approvals and submit for 2 NDA filings; the SMO business supported 61 new drug approvals for customers. The SMO business has supported 317 new drug approvals in total over the past decade, maintaining significant advantages in multiple areas (endocrinology, dermatology, lung cancer and cardiovascular disease, etc.).
• WuXi Biology: Continues to Generate Downstream Opportunities; In Vitro & In Vivo Business Synergies and New Modality Business Drive Growth
  • WuXi Biology follows the science and continuously strengthens drug discovery capabilities in emerging areas. It efficiently generates downstream opportunities for CRDMO model by continuously contributing more than 20% of the Company's new customers.
  • Through platform integration, cross-regional collaboration and comprehensive service transformation, we efficiently enable our customers. WuXi Biology revenue reached RMB1.25 billion in H1 2025, a year-over-year increase of 7.1%. Due to market pricing impact, H1 adjusted non-IFRS gross profit margin was down 0.7pts to 36.4%.
  • We accelerated advancements in in vitro integrated screening technologies and in vivo pharmacology capabilities, driving continued rapid year-over-year revenue growth. The constantly improved competitive edge in non-oncology business has laid a solid foundation for sustained growth throughout the year.
  • New modality drug discovery services continue to perform well, contributing more than 30% of WuXi Biology's total revenue.

[4] As disclosed in the 2025 First Quarterly Report, WuXi Testing here includes only the core business of Continuing Operations (similar to the 2024 baseline).

This release provides a summary of the results and does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For additional information, please refer to the WuXi AppTec 2025 Interim Results Presentation and 2025 Interim Report disclosed on the Company's official website, as well as the Company's disclosure documents and information on the Shanghai Stock Exchange, the Stock Exchange of Hong Kong Limited website. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

Net profit attributable to the owners of the Company is prepared in accordance with China Accounting Standards for Business Enterprises (CAS), in currency of RMB. Besides, all other financial information disclosed in this press release is prepared in accordance with the International Financial Reporting Standards Accounting Standards ("IFRSs"), in currency of RMB.

The 2025 Interim Report of the Company has not been audited.

Second Quarter 2025 Results by Segments
Unit: RMB million
Segment	Revenue	Change	Adjusted non-IFRS Gross Profit	Change	Adjusted non- IFRS Gross Profit Margin
WuXi Chemistry	8,910.40	34.0 %	4,475.02	52.4 %	50.2 %
WuXi Testing	1,396.33	1.6 %	373.99	-27.1 %	26.8 %
WuXi Biology	644.53	6.0 %	235.47	7.8 %	36.5 %
Others	93.89	-55.7 %	67.23	-55.3 %	71.6 %
Discontinued Operations (Note 1)	99.54	-76.1 %	57.93	N/A	58.2 %
Total	11,144.69	20.4 %	5,209.65	38.0 %	46.7 %
First Half 2025 Results by Segments
Unit: RMB million
Segment	Revenue	Change	Adjusted non-IFRS Gross Profit	Change	Adjusted non- IFRS Gross Profit Margin
WuXi Chemistry	16,301.37	33.5 %	7,984.86	49.4 %	49.0 %
WuXi Testing	2,688.65	-1.2 %	675.89	-33.6 %	25.1 %
WuXi Biology	1,251.60	7.1 %	455.89	5.0 %	36.4 %
Others	163.48	-49.6 %	97.31	-48.0 %	59.5 %
Discontinued Operations (Note 1)	394.18	-51.7 %	44.02	N/A	11.2 %
Total	20,799.28	20.6 %	9,257.96	34.9 %	44.5 %
Note 1: In accordance with the IFRSs, the Company has classified the operations for which equity sale agreements were signed or sales were completed during the Reporting Period or the comparison year as discontinued operations.
Note 2: Any sum of the data above that is inconsistent with the total is due to rounding.

Consolidated Statement of Profit or Loss[5] - Prepared under IFRSs
RMB Million	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue	11,144.7	9,259.0	20,799.3	17,240.9
Cost of sales	(6,045.5)	(5,563.8)	(11,687.0)	(10,540.0)
Gross profit	5,099.2	3,695.1	9,112.2	6,700.9
Other income	328.2	269.0	639.5	511.0
Other gains and losses	1,375.7	15.5	2,448.9	208.4
Impairment losses under expected credit losses ("ECL") model, net of reversal	(137.5)	(62.4)	(290.6)	(82.1)
Impairment losses of non-financial assets	(4.0)	-	(73.5)	-
Impairment losses of assets classified as held for sale	(120.7)	-	(120.7)	-
Selling and marketing expenses	(200.3)	(178.4)	(394.4)	(357.5)
Administrative expenses	(649.9)	(667.0)	(1,247.7)	(1,277.5)
R&D expenses	(290.0)	(329.9)	(514.4)	(636.3)
Operating Profit	5,400.5	2,741.9	9,559.4	5,066.8
Share of results of associates	176.3	81.9	240.2	115.8
Share of results of joint ventures	-	(4.4)	0.1	(4.2)
Finance costs	(88.6)	(67.3)	(168.8)	(128.9)
Profit before tax	5,488.1	2,752.2	9,630.8	5,049.6
Income tax expense	(682.6)	(430.2)	(1,247.1)	(768.7)
Profit for the period	4,805.5	2,322.0	8,383.8	4,280.8
Profit for the period attributable to:
Owners of the Company	4,751.1	2,297.6	8,287.3	4,239.8
Non-controlling interests	54.4	24.4	96.4	41.0
	4,805.5	2,322.0	8,383.8	4,280.8
[5] If the sum of the data below is inconsistent with the total, it is caused by rounding.

Consolidated Statement of Profit or Loss [6] (continued) - Prepared under IFRSs
	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Weighted average number of ordinary shares for calculating EPS (expressed in shares)
- Basic	2,834,045,549	2,895,745,826	2,840,111,082	2,907,737,554
- Diluted	2,892,304,153	2,899,828,193	2,897,449,552	2,913,355,532
Earnings per share (expressed in RMB per Share)
- Basic	1.68	0.79	2.92	1.46
- Diluted	1.66	0.79	2.89	1.45
[6] If the sum of the data below is inconsistent with the total, it is caused by rounding.

Consolidated Statement of Financial Position[7] - Prepared under IFRSs
RMB Million	June 30,	December 31,
	2025	2024
Non-current Assets
Property, plant and equipment	25,725.6	25,267.8
Right-of-use assets	1,901.4	1,874.8
Goodwill	971.6	972.4
Other intangible assets	511.7	601.0
Interests in associates	1,887.1	2,322.2
Interests in joint ventures	3.4	3.4
Deferred tax assets	511.1	473.1
Financial assets at fair value through profit or loss ("FVTPL")	8,504.4	8,943.4
Other non-current assets	153.6	114.7
Biological assets	1,065.1	1,063.0
Total Non-current Assets	41,235.0	41,635.7
Current Assets
Inventories	5,293.6	3,532.1
Contract costs	925.8	912.2
Biological assets	931.8	955.5
Amounts due from related parties	85.9	89.3
Trade and other receivables	9,137.4	9,643.7
Contract assets	825.7	988.8
Income tax recoverable	39.8	87.2
Financial assets at FVTPL	2,942.4	1,234.0
Derivative financial instruments	2.6	-
Other current assets	735.6	734.1
Pledged bank deposits	12.2	22.1
Term deposits with initial term of over three months	3,937.5	4,865.6
Bank balances and cash	17,535.5	13,434.3
	42,406.0	36,498.8
Assets classified as held for sale	182.8	2,191.3
Total Current Assets	42,588.7	38,690.2
Total Assets	83,823.8	80,325.8
[7] If the sum of the data below is inconsistent with the total, it is caused by rounding.

Consolidated Statement of Financial Position (continued)[8]- Prepared under IFRSs
RMB Million	June 30,	December 31,
	2025	2024
Current Liabilities
Trade and other payables	7,410.2	7,025.5
Amounts due to related parties	12.5	15.3
Derivative financial instruments	-	202.0
Contract liabilities	2,227.1	2,251.0
Bank borrowings	5,798.2	1,278.6
Lease liabilities	220.9	224.2
Income tax payables	1,296.3	870.8
Convertible bonds	3,517.4	3,493.1
	20,482.6	15,360.6
Liabilities directly associated with assets classified as held for sale	36.4	865.5
Total Current Liabilities	20,518.9	16,226.1
Non-current Liabilities
Bank borrowings	904.9	2,959.5
Deferred tax liabilities	439.4	522.4
Deferred income	959.4	985.6
Lease liabilities	592.1	546.6
Total Non-current Liabilities	2,895.8	5,014.1
Total Liabilities	23,414.7	21,240.2
Net Assets	60,409.1	59,085.6
Capital and Reserves
Share capital	2,872.2	2,888.0
Reserves	57,039.5	55,744.7
Equity attributable to owners of the Company	59,911.7	58,632.7
Non-controlling interests	497.4	452.9
Total Equity	60,409.1	59,085.6
[8] If the sum of the data below is inconsistent with the total, it is caused by rounding.

Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company[9]
RMB Million	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Net profit attributable to the owners of the Company under CAS	4,888.9	2,297.6	8,560.9	4,239.8
GAAP difference[10]	(137.9)	-	(273.6)	-
Net profit attributable to the owners of the Company under IFRSs	4,751.1	2,297.6	8,287.3	4,239.8
Add:
Share-based compensation expenses	142.0	77.2	176.4	165.0
Issuance expenses of convertible bonds	9.8	-	19.6	-
Foreign exchange related losses	270.0	14.6	448.0	29.0
Amortization of acquired intangible assets from merger and acquisition	6.7	13.4	13.8	27.0
Gains or losses from divestiture, restructuring and resource integration initiatives	131.3	-	139.9	-
Non-IFRS net profit attributable to the owners of the Company	5,310.9	2,402.7	9,085.0	4,460.7
Add:
Realized and unrealized (gains)losses from venture capital investments	(1,673.8)	51.9	(2,770.1)	(92.7)
Realized and unrealized share of (gains)losses from joint ventures	(0.0)	4.4	(0.1)	4.2
Adjusted non-IFRS net profit attributable to the owners of the Company	3,637.1	2,459.1	6,314.8	4,372.2
[9] If the sum of the data below is inconsistent with the total, it is caused by rounding.
[10] Due to differences in accounting treatment of long-term equity investments under IFRSs, it occurs GAAP difference of RMB(137.9) million for second quarter of 2025 and RMB(273.6) million for first half of 2025.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients-one collaboration at a time. Learn more at www.wuxiapptec.com.

Forward-Looking Statements

This press release may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends", or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients' intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor an undertaking by WuXi AppTec Co., Ltd. ("WuXi AppTec" or the "Company") to our investors. ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this press release to reflect future events or circumstances, except as required under applicable law.

Continuing Operations and Discontinued Operations

In accordance with the IFRSs, the Company has classified the operations for which equity sale agreements were signed or sales were completed during the Reporting Period or the comparison year as discontinued operations ("Discontinued Operations"). The remaining operations of the Company will continue to be reported as continuing operations ("Continuing Operations").

Use of Non-IFRS and Adjusted Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, foreign exchange-related gains or losses, amortization of acquired intangible assets from merger and acquisition, gains or losses from divestiture, restructuring and resource integration initiatives, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRSs.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRSs. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRSs, or as being comparable to results reported or forecasted by other companies.

SOURCE WuXi AppTec